Abstract:Background and Objective Type 2 diabetes (T2D)-associated periodontitis is severe and refractory in many cases. Considered an inflammatory disease, T2D predisposes to periodontitis by increasing whole-body inflammation. One mechanism of increased inflammation is thatT2D is mediated by loss of production or function of the anti-inflammatory hormone adiponectin. In our previous report, AdipoRon, an adiponectin receptor agonist, and AdipoAI, a newly discovered, more specific agonist, attenuated T2D-associated inflammation by inhibiting osteoclastogenesis and LPS-induced endotoxemia. Autophagy plays an important role during osteoclast differentiation and function. The impact of AdipoAI on osteoclast function and autophagy involved in osteoclastogenesis is not known. Here, we compare AdipoRon and AdipoAI potency, side effects and mechanism of action in T2D-associated periodontitis. Methods The RAW 264.7 cell line was used for in vitro studies. We analyzed the potential cytotoxicity of AdipoAI using the CCK-8 assay. The anti-osteoclastogenic potential of AdipoAI was studied by real-time qPCR and tartrate-resistant acid phosphatase staining. The actions of AdipoAI involved in autophagy were tested by real-time qPCR, western blot and immunofluorescence staining. In the diet-induced obesity model of T2D, we investigated the impact of AdipoAI on fasting blood glucose, alveolar bone loss, and gingival inflammation in mice with experimental periodontitis. Results AdipoRon inhibited osteoclastogenesis and AdipoAI inhibited osteoclastogenesis at lower doses than AdipoRon without any cytotoxicity. In DIO mice with experimental periodontitis, AdipoAI reduced mouse body weight in 14 days, reducing fasting glucose levels, alveolar bone destruction, osteoclast number along the alveolar bone surface, and decreased the expression of pro-inflammatory factors in periodontal tissues. AdipoAI and AdipoRon also enhanced LC3A/B expression when cultured with RANKL.3-Methyladenine, a known autophagy inhibitor, decreased LC3A/B expression and reversed the inhibition of osteoclastogenesis during AdipoAI treatment. Conclusions Our results demonstrate that AdipoAI ameliorates the severity of T2D-associated periodontitis by enhancing autophagy in osteoclasts at lower doses than AdipoRon without demonstrable side effects. Thus, AdipoAI has pharmaceutical potential for treating diabetes-associated periodontal disease.

Adiponectin mRNA Conjugated with Lipid Nanoparticles Specifically Targets the Pathogenesis of Type 2 Diabetes

Adiponectin Regulates Bone Marrow Mesenchymal Stem Cell Niche Through a Unique Signal Transduction Pathway: an Approach for Treating Bone Disease in Diabetes

Adiponectin promotes repair of renal tubular epithelial cells by regulating mitochondrial biogenesis and function

An Adiponectin Receptor Agonist Reduces Type 2 Diabetic Periodontitis.

Cardiac-derived Adiponectin Induced by Long-Term Insulin Treatment Ameliorates Myocardial Ischemia/reperfusion Injury in Type 1 Diabetic Mice Via AMPK Signaling

Reduction Levels and the Effects of High-Molecular-Weight Adiponectin Via AMPK/eNOS in Chinese Type 2 Diabetes.

Multimeric adiponectin nanoparticles regulate glucose metabolism by activating phosphatidylinositol-3-kinase, protein kinase B and T-cadherin

A Novel Adiponectin Receptor Agonist (adipoai) Ameliorates Type 2 Diabetes-Associated Periodontitis by Enhancing Autophagy in Osteoclasts.

The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes.

Antidiabetic features of AdipoAI, a novel AdipoR agonist

Dynamic Alteration Of Adiponectin/Adiponectin Receptor Expression And Its Impact On Myocardial Ischemia/Reperfusion In Type 1 Diabetic Mice

The profile of adiponectin receptors in liver and skeletal muscle of type 2 diabetic rats and its correlation with glucose and lipid metabolism

Cell-Membrane-Coated Cationic Nanoparticles Disguised As Macrophages for the Prevention and Treatment of Type 2 Diabetes Mellitus.

Impaired Adiponectin Signaling Contributes to Disturbed Catabolism of Branched-Chain Amino Acids in Diabetic Mice

Intraperitoneal Administration of the Globular Adiponectin Gene Ameliorates Diabetic Nephropathy in Wistar Rats

New advances of adiponectin in regulating obesity and related metabolic syndromes

Protective Effect of Adiponectin and Its Receptors in Diabetic Nephropathy Rats

Adiponectin and Its Receptors in Diabetic Kidney Disease: Molecular Mechanisms and Clinical Potential

cNPAS2 induced β cell dysfunction by regulating KANK1 expression in type 2 diabetes

Role of Adiponectin in Cardiovascular Diseases Related to Glucose and Lipid Metabolism Disorders

Non‐Cardiotoxic Tetradecanoic Acid‐2,4‐Dinitrophenol Ester Nanomicelles in Microneedles Exert Potent Anti‐Obesity Effect by Regulating Adipocyte Browning and Lipogenesis